AHL6 Antibody

AHLs as Targets for Antibody Development

AHLs are bacterial signaling molecules critical for regulating virulence and biofilm formation in pathogens like Pseudomonas aeruginosa. Antibodies targeting AHLs aim to disrupt quorum sensing, offering a therapeutic strategy against infections .

Table 1: Representative Anti-AHL Antibodies and Properties

Engineering and Validation of Anti-AHL Antibodies

• Light Chain Shuffling: Enhances cross-reactivity and affinity. For example, optimizing the light chain of a parental antibody improved binding to α-neurotoxins by 50-fold .

• Validation Standards:

  • Genetic Strategies: Knockout cell lines confirm specificity .

  • Orthogonal Methods: SPR and ELISA validate binding kinetics .

Table 2: Antibody Validation Metrics

Therapeutic Applications and Challenges

• Infectious Disease: Anti-AHL antibodies block biofilm formation and virulence factor secretion .

• Cancer: Antibody-drug conjugates (ADCs) like chL6 (targeting tumor antigens) show low immunogenicity and effective tumor localization .

• Limitations:

  • Poor stability of AHL analogs during conjugation .

  • Limited tissue penetration in solid tumors .

Emerging Platforms and Datasets

• AVIDa-hIL6: A dataset of 573,891 antigen-antibody pairs for machine learning-driven antibody discovery .

• Recombinant Antibodies: Companies like YCharOS emphasize reproducibility using knockout cell lines .